HYTN Launches GMP Stability Program and Validates Vape Cartridges for International Markets
Source: HYTN Innovations Inc.
February 18, 2025 19:30 ET
HYTN Launches GMP Stability
Program and Validates Vape
Cartridges for International
Markets
VANCOUVER, British Columbia, Feb. 18, 2025 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE:
HYTN, FSE: 85W0, OTC PINK: HYTNF) ("HYTN" or the "Company"), a leader in pharmaceutical-grade
cannabis manufacturing, is pleased to announce the launch of its Good Manufacturing Practice
(GMP) Stability Program and the validation of its cannabis vape cartridges for international
distribution. This initiative builds upon HYTN’s January 21, 2025, announcement of its strategic
partnership with SNDL Inc. to develop GMP-compliant vape products.
The Stability Program is being conducted in collaboration with HYTN’s GMP-licensed laboratory
partner. Upon successful completion, HYTN expects to provide an initial six-month stability
statement for its GMP-compliant vape products—an essential regulatory requirement for
pharmaceutical and medical cannabis markets in most jurisdictions, including Germany, the United
Kingdom, and Australia. Ongoing non-accelerated stability studies aim to extend to 12 months. If
successful, this will further validate long-term product stability for international markets.
In parallel with the launch of the Stability Program, HYTN has nalized the selection of a cartridge
manufacturer and initiated comprehensive qualication and validation procedures, including
equipment qualication and process validation, to ensure compliance with GMP standards for its
ceramic coil 1g vaporizer cartridge. These efforts establish a foundation for global distribution while
ensuring compliance with evolving regulations and market standards.
To support the expansion of its GMP product portfolio to include live resin and live rosin cannabis
vape products, HYTN has submitted an amendment to its existing licensing framework with Health
Canada to incorporate oil as an approved dosage form. This amendment, along with anticipated
additional GMP approvals, reinforces the Company’s commitment to meeting the highest
pharmaceutical and regulatory standards across global markets.
The Company believes that these initiatives further position HYTN to meet the needs of global
cannabis markets requiring GMP-certied products under strict regulatory frameworks. Germany's
medical cannabis market has grown signicantly, driven by increasing patient counts, expanding
physician prescriptions, and broader pharmacy distribution.1 In Q3 2024, Germany imported 20,000
kilograms of cannabis—more than double the quarterly average before the April cannabis reform,
highlighting the rising global demand for pharmaceutical-grade cannabis.1
1. Debra Borchar, Beyond Germany: Other International Markets for Cannabis Opportunities (2025)
About HYTN Innovations Inc.
HYTN Innovations Inc. is a pharmaceutical company specializing in the formulation, manufacturing,
marketing, and sale of products containing psychoactive and psychotropic compounds, including
cannabis-derived cannabinoids and psilocybe-derived tryptamines. HYTN is dedicated to becoming
a premier provider of these products across all federally regulated markets. The Company
accomplishes this by strategically identifying market opportunities and effectively bringing
innovative products to market through its advanced development platform.
About Good Manufacturing Practices (GMP)
GMP guidelines provide guidance for manufacturing, testing, and quality assurance to ensure that
a manufactured product is safe for human consumption or use. Many countries have legislated that
manufacturers follow GMP procedures and create their own GMP guidelines that correspond with
their legislation.
For more information contact:
Elliot McKerr
Chief Executive Ofcer
1.866.590.9289
HYTN Investor Relations:
1.866.590.9289
The Canadian Securities Exchange (CSE) has not reviewed, approved, or disapproved the contents
of this press release.
Certain information contained herein constitutes forward-looking information that involves risks
and uncertainties. Readers are cautioned not to place undue reliance on forward-looking
statements, including, but not limited to, statements regarding the expected outcome of licensing
and certication applications and amendments, the Company’s ability to distribute products in new
markets or in larger quantities in existing markets, and the Company’s ability to maintain
regulatory and licensing requirements. Factors that could cause actual results to vary from forward-
looking statements or may affect the operations, performance, development, and results of the
Company’s business include, among other things: the Company’s inability to successfully obtain
new licenses and certications, or to amend existing ones, and its inability to distribute products
into new markets or in increasing quantities in existing markets, or to continue to maintain
licensing and certication standards; changes in regulatory requirements affecting product
registration or distribution; shifts in market demand for cannabis beverages; competitive factors
within the industry; and general economic and business conditions. Any statements that are not
statements of historical fact are deemed to be forward-looking statements. The forward-looking
statements contained in this news release are made as of the date of this news release, and, except
to the extent required by applicable law, the Company assumes no obligation to update or revise
forward-looking statements made herein or otherwise, whether because of new information, future
events, or otherwise. The forward-looking statements contained in this news release are expressly
qualied by this cautionary note.
